Literature DB >> 22486434

Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors.

Tariq Al-Zaid1, Jeremy S Ditelberg, Victor G Prieto, Dina Lev, Raja Luthra, Michael A Davies, A Hafeez Diwan, Wei-Lien Wang, Alexander J Lazar.   

Abstract

BACKGROUND: Trichilemmoma (TL) can occur as a solitary sporadic lesion usually on the face or as multiple facial lesions almost invariably associated with Cowden syndrome (CS). CS is a multisystem disorder caused by a germline inactivating mutation in PTEN (10q23.31), a tumor suppressor gene. We sought to identify PTEN loss by immunohistochemistry (IHC) in sporadic and CS-associated TL to determine whether IHC is a useful tool to assess an individual for CS.
METHODS: Six TL biopsies associated with CS and 33 biopsies without CS were retrieved. IHC for PTEN was performed. RESULTS were scored as positive (reactivity in TL cells) or negative (no reactivity in TL cells); normal squamous epithelium and vascular endothelium served as internal positive controls.
RESULTS: Complete PTEN loss was noted in 5/6 (83%) CS-associated TL and 1/33 (3%) sporadic (non-CS) TL.
CONCLUSION: Demonstration of complete PTEN loss in TL by IHC is strongly suggestive of association with CS, but retention of PTEN staining does not entirely exclude CS. Therefore, PTEN IHC in TLs may be helpful in screening TL for association with CS, but should be used in context with other established clinical criteria, and possibly germline PTEN genotyping to confirm a diagnosis of CS.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22486434     DOI: 10.1111/j.1600-0560.2012.01888.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

Review 1.  Anal malignant proliferative trichilemmoma: report of a rare case with review of literature.

Authors:  Ang Cui; Zubing Mei; Long Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.

Authors:  Joseph D Khoury; Wei-Lien Wang; Victor G Prieto; L Jeffrey Medeiros; Neda Kalhor; Meera Hameed; Russell Broaddus; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2017-08-24       Impact factor: 12.531

Review 3.  Genodermatosis Affecting the Skin and Mucosa of the Head and Neck: Clinicopathologic, Genetic, and Molecular Aspect--PTEN-Hamartoma Tumor Syndrome/Cowden Syndrome.

Authors:  Vania Nosé
Journal:  Head Neck Pathol       Date:  2016-03-14

4.  Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Authors:  Amanda D Bucheit; Guo Chen; Alan Siroy; Michael Tetzlaff; Russell Broaddus; Denai Milton; Patricia Fox; Roland Bassett; Patrick Hwu; Jeffrey E Gershenwald; Alexander J Lazar; Michael A Davies
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

5.  Stem cell quiescence acts as a tumour suppressor in squamous tumours.

Authors:  A C White; J K Khuu; C Y Dang; J Hu; K V Tran; A Liu; S Gomez; Z Zhang; R Yi; P Scumpia; M Grigorian; W E Lowry
Journal:  Nat Cell Biol       Date:  2013-12-15       Impact factor: 28.824

6.  Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.

Authors:  Jason Roszik; Chang-Jiun Wu; Alan E Siroy; Alexander J Lazar; Michael A Davies; Scott E Woodman; Lawrence N Kwong
Journal:  Sci Rep       Date:  2016-01-20       Impact factor: 4.379

Review 7.  The Skin in Cowden Syndrome.

Authors:  Agnes Lim; Joanne Ngeow
Journal:  Front Med (Lausanne)       Date:  2021-06-10

8.  A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

Authors:  D W Bowles; W W Ma; N Senzer; J R Brahmer; A A Adjei; M Davies; A J Lazar; A Vo; S Peterson; L Walker; D Hausman; C M Rudin; A Jimeno
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.